Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 5, 2025, Imunon, Inc. (IMNN) announced financial results for the second quarter of 2025 and provided a business update.</li><li>The company recently announced the first patient was dosed in the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.</li><li>Three trial sites have been activated thus far, with additional sites, including many from the prior OVATION studies, in the process of being activated.</li></ul>

On August 5, 2025, Imunon, Inc. (IMNN) announced financial results for the second quarter of 2025 and provided a business update.The company recently announced the first patient was dosed in the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.Three trial sites have been activated thus far, with additional sites, including many from the prior OVATION studies, in the process of being activated.

IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial 